Rifaximin in Patients With Diabetic Gastroparesis

Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

Inclusion Criteria

• Men and women adult patients, aged 18-75, with diabetic gastroparesis
• Diagnosis of diabetic gastroparesis will have been made previously using a combination of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (GES; > 20% remaining at 4 hours)

Exclusion Criteria

• Prior surgery to the stomach or esophagus
• Known mechanical obstruction of the GI tract
• Current or recent (< 4 weeks) use of opioids
• Current/active use of cannabis
• Current or recent (< 4 weeks) use of antibiotics
• Current or recent use of antifungal agents (< 4 weeks)
• Prior treatment with rifaximin (< 1 year)
• Uncontrolled diabetes with a HgbA1c > 12
• Severe uncontrolled or untreated anxiety or depression.